摘要
目的:探讨特定血清微小RNA(microRNAs,miRNAs)在B细胞非霍奇金淋巴瘤(B-cell non-Hodgkin's lymphoma,B-NHL)早期诊断中的特异性及其临床价值。方法:选取2020年1月至2023年1月本院收治的115例B-NHL患者作为B-NHL组,另选取同期健康体检者100例作为对照组。采用实时荧光定量聚合酶链反应(qRTPCR)检测两组血清中特定miRNAs(包括miRNA-21与miRNA-155)的表达水平。分析特定miRNAs表达水平与B-NHL患者临床病理特征的关系。采用受试者工作特征曲线(receiver operating characteristic curve,ROC)分析特定miRNAs对B-NHL的诊断效能。结果:B-NHL组血清中miRNA-21与miRNA-155的相对表达量均高于对照组(P<0.05)。不同Ann Arbor分期、B症状、国际预后指数(international prognostic index,IPI)评分、β2-微球蛋白(β2-microglobulin,β2-MG)水平和乳酸脱氢酶(lactate dehydrogenase,LDH)水平的B-NHL组患者血清中miRNA-21与miRNA-155的相对表达量有显著差异。ROC曲线结果显示,血清miRNA-21、miRNA-155单独检测诊断B-NHL的AUC分别为0.796、0.842,灵敏度分别为73.30%、78.29%,特异度分别为78.39%、85.01%,阳性预测值分别为80.19%、86.42%,阴性预测值分别为72.23%、75.90%。联合检测诊断B-NHL的AUC为0.927,高于单独检测,灵敏度为88.35%,特异度为90.01%,阳性预测值为92.22%,阴性预测值为85.73%。结论:血清miRNA-21、miRNA-155在B-NHL患者中呈高表达,且与临床病理特征密切相关,联合检测可提高B-NHL早期诊断效能,并可用于评估患者预后。
Objective to explore the specificity and clinical value of specific serum microRNAs(miRNAs)in the early diagnosis of B-cell non-Hodgkin's lymphoma(B-NHL).Methods A total of 115 patients with B-NHL admitted to our hospital from January 2020 to January 2023 were selected as the B-NHL group,and another 100 healthy individuals who underwent physical examinations during the same period were selected as the control group.The expression levels of specific miRNAs(including miRNA-21 and miRNA-155)in the serum of both groups were detected by real-time fluorescence quantitative polymerase chain reaction(qRT-PCR).The relationship between the expression levels of specific miRNAs and the clinical pathological characteristics of B-NHL patients was analyzed.The diagnostic efficacy of specific miRNAs for B-NHL was analyzed by receiver operating characteristic curve(ROC).Results The relative expression levels of miRNA-21 and miRNA-155 in the serum of the B-NHL group were both higher than those of the control group(P<0.05).There are significant differences in the relative expression levels of miRNA-21 and miRNA-155 in the serum of B-NHL group patients with different Ann Arbor stages,B symptoms,International Prognostic Index(IPI)scores,β2-microglobulin(β2-MG)levels and lactate dehydrogenase(LDH)levels(P<0.05).The results of the ROC curve showed that the AUCs of serum miRNA-21 and miRNA-155 alone in the diagnosis of B-NHL were 0.796 and 0.842,respectively,the sensitivities were 73.30%and 78.29%,respectively,and the specificities were 78.39%and 85.01%,respectively.The positive predictive values were 80.19%and 86.42%respectively,and the negative predictive values were 72.23%and 75.90%respectively.The AUC of the combined detection for diagnosing B-NHL was 0.927,which was higher than that of the single detection,with a sensitivity of 88.35%,a specificity of 90.01%,a positive predictive value of 92.22%,and a negative predictive value of 85.73%.Conclusion serum miRNA-21 and miRNA-155 are highly expressed in patients with B-NHL and are closely related to clinical pathological features.The combined detection can improve the early diagnostic efficiency of B-NHL and can also be used to evaluate the prognosis of patients.
作者
渠姣燕
张越
霍鸿佳
周合冰
QU Jiaoyan;ZHANG Yue;HUO Hongjia;ZHOU Hebing(Department of Hematology,Beijing Luhe Hospital,Capital Medical University,Beijing 101149)
出处
《晓庄学院学报(医学版)》
2025年第3期89-93,共5页
Journal of Hunan Normal University(Medical Sciences)
基金
北京市通州区科技计划“m6A去甲基化酶FTO通过调控miR-203成熟参与多发性骨髓瘤发生发展的研究”(KJ2022CXO34)
